HealthScience and Research
BioNTech and Bristol Myers report 36.7% response in lung-cancer trial
Pumitamig plus docetaxel showed early activity after immunotherapy and chemotherapy, but the Phase 2 study had no control arm.
Summit Therapeutics reports 25% lower death risk in biliary-cancer trial
Ivonescimab plus chemotherapy extended median survival to 14.9 months in a China-only study, with a separate U.S. trial planned.
HealthScience and Research
Xencor reports 45.5% confirmed response at selected kidney-cancer dose
Severe or worse treatment-related adverse events affected 72.1 per cent across expansion cohorts; FDA talks are planned for 2027.
Analysis
Genmab reports 75% first-line response in petosemtamab colorectal study
The single-arm analysis includes unconfirmed responses and supports two enrolling Phase 3 trials; median response duration was not disclosed.
Health
NYSE: LLYLilly reports 14.5‑month response duration with olomorasib lung-cancer combination
The uncontrolled first-line analyses support continued development, with randomized SUNRAY-01 results expected in the first half of 2027.
CannabisStock News
Canopy Growth Corporation shareholders authorize up to 1‑for‑15 reverse split
Directors retain discretion over the ratio for common and exchangeable shares, with no effective date set in the voting disclosure.
HealthScience and Research
Climb Bio reports 38% immunologic remission in kidney trial
Five of 13 patients reached immunologic remission at 12 weeks, while higher-dose cohorts and longer follow-up will guide development.
Technology
NSE: STLTECHA US$1.2 billion agreement spans 2026 to 2030, while a one-time tariff refund lifted the September quarter’s reported earnings.
Health
NASDAQ: GMABGenmab will conduct the Phase 1/2 study, while Incyte will co-fund it and supply its KRAS G12D inhibitor; a start date was not disclosed.
Analysis
Teck Resources reports reduced capacity at Highland Valley as strike begins
USW Local 7619 represents about 1,200 workers at the B.C. copper operation, whose production loss has not been quantified.
Latest
Intelligent Protection Management agrees to buy AdTech business for up to US$2.7M
The California services acquisition would close in two stages, with cash, a seller note and an earnout subject to separate utility approvals.
TinOne Resources plans November tin and tungsten drilling in Tasmania
Rigs are secured for approved drilling at Aberfoyle and Great Pyramid, while separate tailings work awaits regulatory approval.
Atlas Energy Solutions closes US$424M bridge loan for data centre equipment
The delayed draw facility starts with US$171 million borrowed and a 180-day maturity, with an extension tied to supply agreements and lender consent.
Canagold Resources drills 52.8 g/t gold over 4.64m at New Polaris
The interval also returned 0.83 per cent antimony, but true widths remain unknown after the completed 14-hole campaign.
Teleflex gains FDA breakthrough designation for Freesolve coronary scaffold
A 1,859-patient pivotal trial will compare the resorbable implant with Xience, with primary completion estimated for June 2029.
Spartan Metals expands Victorio measured and indicated resource by 9.5%
The estimate uses a higher value cutoff and revised metal prices ahead of a fourth-quarter economic study of the New Mexico project.
Mentioned this week
Mining & Critical Minerals
Gold, silver, uranium, lithium, copper and rare earths: the producers, the developers and the projects behind them.
View all
EnergyUranium
Finland grants Posiva nuclear waste disposal licence through 2070
Fortum's jointly owned disposal company must complete commissioning and pass a STUK inspection before operations can begin.
Health & Science
Medical and pharmaceutical developments, psychedelics, and the research and safety questions around them.
View all
Health
NYSE: PFEA 401-infant presentation compared immune responses and safety with Prevnar 20; the company has not dated its pediatric Phase 3 readout.
Markets & Technology
Technology, computing, crypto and cannabis, and the listed companies moving in them.
View all
EnergyTechnology
Alphabet's Google expands Voltus virtual power plant agreement to 1 GW
Google will fund flexible household and business resources in PJM, but the companies disclose no price or delivery schedule.
Technology
NASDAQ: BTDRBitdeer Technologies Group sells all 283.4 BTC in weekly tally
Proprietary bitcoin holdings remained at zero as of Oct. 23, while the update omitted sale prices and cash proceeds.
Energy
Uranium, lithium, oil and gas, hydrogen and the grid: the fuels and the companies behind them.
View all
Energy
LON: IESThe National Wealth Fund is providing £12.2 million, with admission targeted for Nov. 12 subject to shareholder approval.
Energy
NASDAQ: NNEAn initial study is estimated at six months; NANO disclosed no retainer amount, fabrication price or component delivery date.
Uranium
TSE: CCOConstruction is underway on a commercial LEU+ factory, with listed owners Cameco and Brookfield Renewable exposed through their Westinghouse interests.
Cannabis & Psychedelics
Licensed producers, retail, policy, and the psychedelics companies moving through the clinic.
View all
Psychedelics
CNSX: OPTIThe capsules are intended for three programs, including a Canadian Phase 3 PTSD trial of up to 100 people expected to begin in 2027.
Cannabis
TSE: OGIThe province estimates illegal retailers take 30 per cent of cannabis sales and proposes inspection, seizure and penalty powers for the AGCO.
Cannabis
TSE: CURAThe bid offers US$1 in cash plus 0.4013 Curaleaf shares for each Aurora share, with a Dec. 4 tender deadline.
Cannabis
TSE: CRONCash earnouts tied to 2026 and 2027 earnings add to the base price for a grower supplying nearly all 69 shops in the Dutch pilot.